AlphaCrest Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

AlphaCrest Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-19,351	Closed	-$138K	–	1204
2020 Q1	$138K	Sell	19,351 -8,835	-31%	-$110K	0.02%	972
2019 Q4	$673K	Buy	28,186 +74	+0.3%	+$2.04K	0.06%	592
2019 Q3	$754K	Buy	28,112 +17,989	+178%	+$505K	0.05%	710
2019 Q2	$275K	Buy	+10,123	New	+$317K	0.02%	887

Other funds holding PTLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

AlphaCrest Capital Management's PTLA Position: Q2 2020 in Review

AlphaCrest Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 19,351 shares — an estimated $138K sold.

AlphaCrest Capital Management first reported a position in PTLA in Q2 2019 and held it in 4 quarters. The position peaked at $754K in Q3 2019. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

AlphaCrest Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
AlphaCrest Capital Management sold 19,351 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $138K.
AlphaCrest Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q2 2019 and held it in 4 quarters.
AlphaCrest Capital Management's Portola Pharmaceuticals, Inc. position peaked at $754K in Q3 2019.
162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on AlphaCrest Capital Management's 13F filing for Q2 2020, filed 12 Aug 2020.